vs
GLAUKOS Corp（GKOS）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是GLAUKOS Corp的3.8倍（$540.7M vs $143.1M）。ICU MEDICAL INC净利率更高（-2.9% vs -93.4%，领先90.5%）。GLAUKOS Corp同比增速更快（35.7% vs -14.1%）。ICU MEDICAL INC自由现金流更多（$36.0M vs $3.9M）。过去两年GLAUKOS Corp的营收复合增速更高（29.3% vs -2.3%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
GKOS vs ICUI — 直观对比
营收规模更大
ICUI
是对方的3.8倍
$143.1M
营收增速更快
GKOS
高出49.8%
-14.1%
净利率更高
ICUI
高出90.5%
-93.4%
自由现金流更多
ICUI
多$32.0M
$3.9M
两年增速更快
GKOS
近两年复合增速
-2.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $143.1M | $540.7M |
| 净利润 | $-133.7M | $-15.7M |
| 毛利率 | -1.1% | 37.5% |
| 营业利润率 | -97.7% | 1.0% |
| 净利率 | -93.4% | -2.9% |
| 营收同比 | 35.7% | -14.1% |
| 净利润同比 | -298.0% | 34.0% |
| 每股收益（稀释后） | $-2.34 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GKOSICUI
| Q4 25 | $143.1M | $540.7M | ||
| Q3 25 | $133.5M | $537.0M | ||
| Q2 25 | $124.1M | $548.9M | ||
| Q1 25 | $106.7M | $604.7M | ||
| Q4 24 | $105.5M | $629.8M | ||
| Q3 24 | $96.7M | $589.1M | ||
| Q2 24 | $95.7M | $596.5M | ||
| Q1 24 | $85.6M | $566.7M |
净利润GKOSICUI
| Q4 25 | $-133.7M | $-15.7M | ||
| Q3 25 | $-16.2M | $-3.4M | ||
| Q2 25 | $-19.7M | $35.3M | ||
| Q1 25 | $-18.1M | $-15.5M | ||
| Q4 24 | $-33.6M | $-23.8M | ||
| Q3 24 | $-21.4M | $-33.0M | ||
| Q2 24 | $-50.5M | $-21.4M | ||
| Q1 24 | $-40.8M | $-39.5M |
毛利率GKOSICUI
| Q4 25 | -1.1% | 37.5% | ||
| Q3 25 | 78.4% | 37.4% | ||
| Q2 25 | 78.3% | 37.9% | ||
| Q1 25 | 77.2% | 34.7% | ||
| Q4 24 | 72.9% | 36.1% | ||
| Q3 24 | 76.6% | 34.8% | ||
| Q2 24 | 76.4% | 34.8% | ||
| Q1 24 | 76.3% | 32.7% |
营业利润率GKOSICUI
| Q4 25 | -97.7% | 1.0% | ||
| Q3 25 | -12.3% | 2.6% | ||
| Q2 25 | -18.3% | 1.9% | ||
| Q1 25 | -19.4% | 2.1% | ||
| Q4 24 | -27.2% | 6.0% | ||
| Q3 24 | -25.5% | 1.4% | ||
| Q2 24 | -31.3% | 1.3% | ||
| Q1 24 | -45.6% | -1.9% |
净利率GKOSICUI
| Q4 25 | -93.4% | -2.9% | ||
| Q3 25 | -12.2% | -0.6% | ||
| Q2 25 | -15.8% | 6.4% | ||
| Q1 25 | -17.0% | -2.6% | ||
| Q4 24 | -31.8% | -3.8% | ||
| Q3 24 | -22.1% | -5.6% | ||
| Q2 24 | -52.8% | -3.6% | ||
| Q1 24 | -47.7% | -7.0% |
每股收益（稀释后）GKOSICUI
| Q4 25 | $-2.34 | $-0.63 | ||
| Q3 25 | $-0.28 | $-0.14 | ||
| Q2 25 | $-0.34 | $1.43 | ||
| Q1 25 | $-0.32 | $-0.63 | ||
| Q4 24 | $-0.56 | $-0.97 | ||
| Q3 24 | $-0.39 | $-1.35 | ||
| Q2 24 | $-1.00 | $-0.88 | ||
| Q1 24 | $-0.82 | $-1.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.8M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $656.2M | $2.1B |
| 总资产 | $893.5M | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GKOSICUI
| Q4 25 | $90.8M | — | ||
| Q3 25 | $98.2M | — | ||
| Q2 25 | $100.8M | — | ||
| Q1 25 | $114.3M | — | ||
| Q4 24 | $169.6M | $308.6M | ||
| Q3 24 | $100.1M | $312.5M | ||
| Q2 24 | $68.1M | $302.6M | ||
| Q1 24 | $42.5M | $251.4M |
股东权益GKOSICUI
| Q4 25 | $656.2M | $2.1B | ||
| Q3 25 | $769.5M | $2.1B | ||
| Q2 25 | $765.1M | $2.1B | ||
| Q1 25 | $764.0M | $2.0B | ||
| Q4 24 | $766.9M | $2.0B | ||
| Q3 24 | $668.5M | $2.0B | ||
| Q2 24 | $665.2M | $2.0B | ||
| Q1 24 | $450.7M | $2.1B |
总资产GKOSICUI
| Q4 25 | $893.5M | $4.1B | ||
| Q3 25 | $999.4M | $4.1B | ||
| Q2 25 | $987.0M | $4.1B | ||
| Q1 25 | $966.2M | $4.2B | ||
| Q4 24 | $974.8M | $4.2B | ||
| Q3 24 | $926.5M | $4.3B | ||
| Q2 24 | $919.7M | $4.3B | ||
| Q1 24 | $933.3M | $4.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.8M | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $36.0M |
| 自由现金流率自由现金流/营收 | 2.7% | 6.6% |
| 资本支出强度资本支出/营收 | 2.0% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-22.5M | $91.8M |
8季度趋势，按日历期对齐
经营现金流GKOSICUI
| Q4 25 | $6.8M | $60.6M | ||
| Q3 25 | $-10.1M | $56.7M | ||
| Q2 25 | $7.0M | $11.2M | ||
| Q1 25 | $-18.5M | $51.3M | ||
| Q4 24 | $507.0K | $40.2M | ||
| Q3 24 | $-9.6M | $36.1M | ||
| Q2 24 | $-18.4M | $82.0M | ||
| Q1 24 | $-33.9M | $45.8M |
自由现金流GKOSICUI
| Q4 25 | $3.9M | $36.0M | ||
| Q3 25 | $-11.7M | $27.6M | ||
| Q2 25 | $5.8M | $-8.5M | ||
| Q1 25 | $-20.5M | $36.7M | ||
| Q4 24 | $-1.2M | $16.1M | ||
| Q3 24 | $-11.0M | $16.2M | ||
| Q2 24 | $-20.5M | $62.5M | ||
| Q1 24 | $-34.8M | $29.9M |
自由现金流率GKOSICUI
| Q4 25 | 2.7% | 6.6% | ||
| Q3 25 | -8.8% | 5.1% | ||
| Q2 25 | 4.7% | -1.5% | ||
| Q1 25 | -19.2% | 6.1% | ||
| Q4 24 | -1.2% | 2.6% | ||
| Q3 24 | -11.4% | 2.7% | ||
| Q2 24 | -21.4% | 10.5% | ||
| Q1 24 | -40.7% | 5.3% |
资本支出强度GKOSICUI
| Q4 25 | 2.0% | 4.6% | ||
| Q3 25 | 1.2% | 5.4% | ||
| Q2 25 | 0.9% | 3.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 1.6% | 3.8% | ||
| Q3 24 | 1.5% | 3.4% | ||
| Q2 24 | 2.2% | 3.3% | ||
| Q1 24 | 1.1% | 2.8% |
现金转化率GKOSICUI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
